Demographic characteristics of liver transplant recipient with SARS-CoV-2 infection
| Study population | Results |
| Patients, n | 57 |
| Sex, male, n (%) | 40 (70) |
| Ethnicity, Caucasian, n (%) | 53 (93) |
| Age, years, median (IQR) | 65 (57–70) |
| Age ≥65, n (%) | 29 (51) |
| Age <65, n (%) | 28 (49) |
| BMI, kg/m2, mean (SD) | 26.0±4.6 |
| BMI, classes, n (%) | |
| 18–24.9 | 23 (43) |
| 25–29.9 | 23 (43) |
| >30 | 8 (14) |
| Time from transplant to diagnosis, years, median (IQR) | 6 (2–13) |
| Very long-term transplant recipients, n (%) | 21 (37) |
| Very short-term transplant recipients, n (%) | 11 (19) |
| Long-term transplant recipients, n (%) | 32 (56) |
| Indication to LT, n (%) | |
| End-stage liver disease | 38 (68) |
| Liver tumour | 16 (29) |
| Acute liver failure | 4 (7) |
| Other | 9 (16) |
| Underlying liver disease, n (%) | |
| ALD | 15 (26) |
| Viral | 24 (42) |
| HCV | 11 (19) |
| HBV | 13 (23) |
| PSC | 3 (5) |
| PBC | 4 (7) |
| NAFLD/NASH | 2 (4) |
| Autoimmune | 1 (2) |
| Hemochromatosis | 1 (2) |
| Wilson’s disease | 1 (2) |
| Other | 10 (18) |
| HCC, yes, n (%) | 20 (35) |
| Comorbidities, n (%) | |
| Cardiovascular disease | 21 (37) |
| Coronary artery disease | 7 (12) |
| Heart failure | 9 (16) |
| Atrial fibrillation | 6 (11) |
| Stroke | 1 (2) |
| Other | 8 (14) |
| >1 cardiovascular disease | 10 (18) |
| Arterial hypertension | 32 (56) |
| Diabetes mellitus | 21 (37) |
| Active cancer | 5 (9) |
| Kidney insufficiency | 16 (28) |
| Respiratory disease | 13 (23) |
| COPD | 7 (12) |
| HIV | 1 (2) |
| Smoke history, yes, n (%) | 7 (12) |
| Symptoms at presentation, n (%) | |
| Fever | 44 (79) |
| Cough | 31 (55) |
| Dyspnoea | 26 (46) |
| Fatigue and myalgia | 32 (56) |
| GI symptoms | 18 (33) |
| Diarrhoea | 16 (28) |
| Abdominal pain | 1 (2) |
| Vomiting | 1 (2) |
| Anosmia or dysgeusia | 4 (7) |
| Other | 8 (14) |
| Concomitant bacterial infection, n (%) | 9 (16) |
| Suspected | 3 (6) |
| Confirmed | 6 (11) |
ALD, alcoholic liver disease; BMI, body mass index; COPD, chronic obstructive pulmonary disease; HCC, hepatocellular carcinoma; LT, liver transplantation; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis.